Platelet and leukocyte deposition onto metallic struts can be crucial factors in determining the outcome of a coronary stenting procedure. By means of an invitro closed-loop circulation model, we aimed to assess blood-stent interaction patterns for a novel stainless-steel stent (MultiLink).
INTRODUCTION
The appearance of stents in the early '90s resulted in a significant reduction in short-and long-term complications after coronary angioplasty 1 , and changed the scenario of catheter-based coronary interventions dramatically 2 . Since then, new models of stents have been continuously developed, but, despite the fascinating innovations, many of them failed in proving better clinical results than their predecessor, the Palmaz Schatz stent 3, 4 . Due to the refinement of the adjunctive antiplatelet treatment 5 and the establishment of the most appropriate ways for stent utilisation 6 , the occurrence of in-stent subacute thrombosis has been reduced, but it still remains as a scary complication, due to its strong impact on short-term mortality 7 . Moreover, the late reappearance of a coronary stenosis at the site of intervention (restenosis) is a problem that has not been completely solved by stents, as it still affects 10-30% of the percutaneously-treated atherosclerotic lesions 8 . In-stent subacute thrombosis and restenosis originate from the same source: the immediate local deposition of platelets and leukocytes onto the bare metal surface can lead to abrupt lumen obliteration, but also enhances the release of cytokines and growth factors, thus promoting the gradual proliferation of smooth muscle cells into the vessel wall 9 . It is of prime importance to understand how the characteristics of stents (composition, geometry, size) influence their haemocompatibility, intended as their propensity to interact with blood components. Till now, most of the experimental studies, aiming to investigate the haemocompatibility of stents, have been performed on animal models, but the phenomena observed in this subset cannot be a-critically translated into the human coronary environment 10 . Although the MultiLink, a stainless-steel stent of new generation, has shown promising features for reducing the procedure-related adverse events 11 , its haemocompatibility has not been elucidated yet.
The purpose of the present study was to evaluate, by means of a new model system of in-vitro blood circulation 12 : the propensity of MultiLink to promote platelet and leukocyte deposition; the impact of MultiLink on circulating blood cells and blood activation; the effect of single antiplatelet treatment in preventing platelet deposition.
METHODS

Study design
The study was set as a comparison between MultiLink stent and a gold standard stent (Palmaz Schatz). An in-vitro closed loop circulation model was used to simulate blood circulation. The effects of stents on blood cells and blood activation were tested by blood assays on re-circulated blood. Platelet and leukocyte adhesion to stents after circulation were investigated both by immunofluorocytometry and scanning electron microscopy. The effect of antiplatelet treatment on blood-stent interaction was also evaluated.
Stents
Coronary stents used for experiments were: ACS RX MultiLink HP ® , balloon-mounted (Guidant Nederland BV, Nieuwegein, The Netherlands) (n=20) and PS-153 Palmaz Schatz ® (Cordis Nederland BV, Roden, The Netherlands) (n=20). Both stents were 15 mm long and made with the same metallic alloy (316L stainless steel), but they differed in geometry. Palmaz Schatz is composed by two 7.0 mm-long segments, connected by a 1.0 mm long longitudinal bridge. Each segment is manufactured from a solid tube with eight rows of staggered-offset slots, etched by electromagnetic discharge, that assume a diamond shape after expansion. MultiLink is a laser-cutted multicellular stent, made by 12 corrugated rings, each interconnected with the other by 3 longitudinal bridges, which assume a rounded shape after expansion (Figure 1 ). Polishing procedures are similar for both devices 13 .
In-vitro closed-loop circulation model
A standardised closed-loop system was constructed by means of silicone rubber tubing (3.0 mm internal diameter) and a barely-occlusive roller pump. This circuit was partially immersed in a water bath at 37 o C (Figure 2 ). To minimise blood activation by the circuit itself, each circuit was pre-coated with human albumin.
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Stents used for the experiments were fixed in a reservoir of the silicon tubing by means of their delivery system. Empty circuits (n=20) were also tested to assess the blood activation by the system itself.
Fifty ml of heparinised (1 IU heparin/ml) human whole blood was obtained by healthy volunteers and divided into two aliquots: to one of them indomethacin was added. As reported in previous experimental studies 14 , this drug is able to reduce, by irreversibly blocking cyclo-oxygenase and without the need for metabolic conversion, the release of thromboxane by activated platelets. In the concentration used for our model (15 µg/ml), this treatment mimics the antiplatelet effect of acetylsalicylic acid at the oral dosage of 325 mg, which is its recommended daily administration, for patients submitted to stent implantation. For each experiment, 4 mL of blood were slowly injected with a syringe in the system until no air was left and re-circulated for 15 minutes through the tubing at a flow rate of 40 ml/min. Each stent was tested in a separate, cleansed and sterilised circuit.
Whole blood and plasma assays
Re-circulated blood from each experimental group was tested for haematocrit, erythrocyte, leukocyte and platelet counts (cell deposition or damage), free haemoglobin (erythrocyte damage), prothrombin fragment 1+2 (activation of the coagulation system), complement C5b-9 (activation of the complement system), β-thromboglobulin ( mechanically-induced platelet activation), thromboxane B2 (platelet activation), elastase (leukocyte activation). Both whole blood and plasma assays were performed in duplicate, as previously described 12 .
Immunofluorocytometry
Platelet and leukocyte adhesion onto removed stents was tested by means of specific europium-labelled antibodies, respectively for the GpIIIa receptor CD61 (M753, Dakopatts, Glostrup, Denmark), and the receptor CD11b (M741), as previously described 12, 15 . Results are presented as counts per second corrected for stent weight (cps/stent).
Assuming that platelets can become activated by shear forces occurring during blood passage through stents, in the latest experiments platelet deposition was assessed also in a tract of the circuit tube immediately distal to MultiLink (n=7) and Palmaz Schatz (n=3). 
Scanning electron microscopy
Scanning electron microscopy was performed on MultiLink (n=3) and Palmaz Schatz (n=3), randomly selected among each experimental group. Before microscopy, stents were washed, incubated in a glutaraldehyde solution to fix the adherent blood components, and dehydrated in ethanol series. After critical point drying, samples were sputtercoated with gold and examined with FEG-SEM at 2kV (Jeol 6301 F, Tokyo, Japan).
Statistical analysis
Normal-distributed variables were reported as Mean and Standard deviation. Not normal-distributed variables were reported as Median and Range (Min-Max), and they underwent logarithmic transformation before analysis.
Two-way ANOVA was performed to assess any difference in cell damage or blood activation between MultiLink, Palmaz Schatz, and empty circuits, and in platelet and leukocyte adhesion between MultiLink and Palmaz Schatz stents. The ANOVA model was constructed including as variables: stent, antiplatelet treatment, and their interaction. If a clinically relevant interaction was found, values for the interaction term were reported. If no interaction was found, results were presented for stent variable (corrected for antiplatelet treatment). Thromboxane B2 values were presented also for antiplatelet treatment variable (corrected for stent).
All statistical analyses were performed using SAS, Windows version 6.12 (SAS, Cary NC, USA).
RESULTS
Whole blood assays
No significant interaction for stent and antiplatelet treatment, nor any significant difference between empty circuits, MultiLink and Palmaz Schatz stents was found, in regards to haematocrit, erythrocyte-, and leukocyte-count.
Platelet-count was mildly reduced in the presence of indomethacin both for MultiLink (from 120±24 to 105±34 10 9 /L), and Palmaz Schatz (from 121±28 to 107±26 10 9 /L), while it increased in empty circuit where indomethacin was present (from 92±27 to 123±41 10 9 /L) (p=0.042 for interaction stent/antiplatelet treatment).
Plasma assays
No significant interaction for stent and antiplatelet treatment, or any significant difference between empty circuits, MultiLink, and Palmaz Schatz stents was found, in regards to free haemoglobin, prothrombin fragment 1+2, complement C5b-9, β-thromboglobulin, and elastase.
However, giving evidence for an effective blockade of activated platelets, thromboxane B2 concentrations were significantly reduced in the experiments where indomethacin was present (from 454±367 to 44±36 pg/mL; p=0.001).
Results for whole blood and plasma assays are extensively reported in Table 1 .
Immunofluorocytometry
Indomethacin significantly reduced platelet adhesion to MultiLink (from 3.78±1.28 to 2.23±0.57 x10 6 cps/stent), but not to Palmaz Schatz (from 4.11±0.31 to 5.02±1.29 x10 6 cps/stent)(p=0.011 for interaction stent/antiplatelet treatment) (Figure 3) .
No significant interaction for stent and antiplatelet treatment was found, regarding platelet adhesion to the circuit tube distal to stents. However, circuit tubes distal to MultiLink showed a tendency towards reduction when indomethacin was present (from 5.05±0.64 to 2.93±1.04 x10 3 cps/mg). Leukocyte adhesion to MultiLink was significantly less, when compared to Palmaz Schatz (7.95±1.59 vs. 9.16±1.36 x10 6 cps/stent; p=0.016), regardless of the presence of indomethacin (Figure 4 ). 
Leukocyte adhesion to MultiLink and Palmaz Schatz stent as determined by immunofluorocytometry. Full circles (·) and empty circles (o) represent experiments in the absence (No IMC) and in the presence (IMC) of indomethacin, respectively. Mean±SD is also shown for both groups. Leukocyte adhesion to MultiLink is less, compared to Palmaz Schatz, regardless of the presence of antiplatelet treatment (p=0.016).
Scanning electron microscopy
Scanning electron microscopy pictures of MultiLink, when indomethacin was not present, showed a deposition of platelets onto a protein layer. Each deposited platelet had multiple expressed pseudopodia interacting with the biomaterial and/ or neighbouring platelets ( Figure 5 -panel A) . On the other hand, when indomethacin was present in the circulating system, platelets were deposited to a somewhat lesser extent and they were visible as round-shaped elements, not spread onto the surface of the stents ( Figure 5 -panel B) . 
A B
Scanning electron microscopy pictures of Palmaz Schatz, when indomethacin was not present, showed platelet accumulation without full-spread platelets. As not seen for MultiLink, small particles of approximately 0.2-0.3 mm in diameter (platelet vesicles) were also observed onto the bare stent material. Erythrocytes entrapped in fibrin strands were also visible ( Figure 6 -panel A) . When indomethacin was present in the circulating system, "activated" platelets were still demonstrable: pseudopodia-provided platelets were superimposed onto a layer of flattened platelets, directly deposited onto a protein layer material or on the bare stent. Platelet vesicles were still clearly visible ( Figure 6 -panel B) . 
Systemic and local effects of coronary stents
It has been hypothesised that the deployment of a stent in the coronary system can have repercussions on circulating blood cells 16 . However, as demonstrated in the present study, erythrocytes, platelets, and leukocytes did not suffer from a significant damage, and, after stent placement, the markers of blood and cell activation remained unchanged. Nevertheless, as clearly visible in our scanning electron microscopy pictures, stents represent a trigger for blood and cell reaction at the site of deployment.
It is a well-known evidence that stents can activate the coagulation cascade by promoting the formation of thrombin on the damaged vessel wall. However, their metal structures can also have a direct catalysing effect in transforming fibrinogen into fibrin. In this way, platelets are enabled to adhere onto the fibrin layer, already formed on the stent surface, and to get activated 17 . Platelet binding becomes then irreversible, and can promote more thrombus formation and leukocytes adhesion through an inflammatory-mediated mechanism. Then, through the release of cytokines and growth factors, smooth muscle cells are induced to migrate and replicate, and intimal hyperplasia and restenosis can develop 18 . In the present study we demonstrated that stents' characteristics are an important issue in modulating blood-stent interaction.
Stent's features and haemocompatibility
Some studies have suggested that composition, surface covering, and/or electrical charge 19, 20, 21 could be important in determining the haemocompatibility of stents. Our study brings forth the further knowledge that, even when made by the same material, stents can show a different behaviour in terms of haemocompatibility. In fact, in our experimental model, MultiLink and Palmaz Schatz, which are both 316L stainless-steel stents, have different attitudes in promoting platelet and leukocyte adhesion.
Despite its long-established clinical usefulness 1 , in our experimental model Palmaz Schatz showed a higher propensity to stick circulating blood cells than MultiLink. Other than the composition, probably also the geometry of the stent's body and the distribution of the stent's struts play a determinant role in the biocellular reaction after stent implantation.
As early reported by Rogers et al., stent design can determine the incidence both of experimental thrombosis and restenosis 22 . More recently Garasic et al. 23 , by means of an animal model, showed that stents forming a more circular crosssectional area are associated with 50-60% drop in mural thrombus, and a two-fold reduction in neointimal thickening after stenting. No difference was shown by these authors in relation with stent thickness, while an increased number of struts was related to a higher parietal inflammatory response. These results confirmed both the findings of Carter et al. 24 who investigated how symmetric expansion, uniform arterial wall coverage, longitudinal flexibility, and radial strength have positive repercussions on the response to stents, and of Schultz et al. 25 who found that those stents, which are more prone to asymmetric expansion, can induce a higher rate of restenosis.
Due to its particular multicellular structure, MultiLink shows a high radial stability and plastic ductility, small strut-to-strut gaps, and a low profile, thus probably exerting less rheologic and biochemical impact.
Antiplatelet treatment for coronary stenting
As confirmed by our findings, an adequate antiplatelet treatment positively interferes with platelet aggregation after stenting.
It has already been demonstrated that antiaggregant therapy alone is able to prevent the risk of in-stent subacute thrombosis, with a beneficial reduction in haemorrhagic complications 5 . The currently recommended antiplatelet treatment after stenting (Aspirin + Ticlopidine or Clopidogrel) has been standardised after experimental and clinical observations with Palmaz Schatz. However, while the lifethreatening occurrence of thrombotic thrombocytopenic purpura is reported after Ticlopidine or Clopidigrel treatment 26 , on the other hand it has been demonstrated that, in particular conditions (for ex. optimal stent expansion, assessed by intravascular ultrasound), patients can profit by acetylsalicylic acid alone 27 . In our study, MultiLink took advantage of a drug regimen, corresponding to the in-vivo administration of acetylsalicylic acid alone. These results coincide with the clinical findings of Calver et al. 28 , who proved that this is an effective and safe antiplatelet treatment after MultiLink implantation and have also been confirmed by a randomised trial (WEST-2), aiming to assess the feasibility of single antiplatelet treatment when MultiLink was used 29 .
Clinical implications of blood-stent interaction
To cope with the continuing technological evolution of coronary interventional devices, manufacturers often release stents lacking satisfactory proofs of their performances, particularly in terms of haemocompatibility. Furthermore, the population of cardiopathic patients submitted to percutaneous interventions undergoes continuous evolution. Stenting procedures have been lately implemented in the treatment of patients suffering from acute coronary syndromes (unstable angina, acute myocardial infarction). Many pivotal trials have demonstrated that in such patients an effective blockade of activated GPIIbIIIa receptors positively influences the short-and longterm outcome after stenting, by reducing the risk of subacute thrombosis, by optimising the blood flow in the tributary microcirculation, and by possibly preventing the development of restenosis 30 . Also patients affected by diabetes mellitus, progressed in years, or in whom particularly complex coronary lesions have been detected, seem to benefit by stent usage, more than by PTCA alone 31, 32 . In this continuously evolving scenario, the propensity of a stent to tether platelets and leukocytes, and eventually to promote subacute thrombosis and restenosis, becomes a very important bias in predicting their outcomes.
Our experimental findings can justify the promising results of MultiLink, which has demonstrated in a clinical setting an extremely low rate of subacute thrombosis (0.9%), restenosis (12%), and late major cardiac events (17%) 33 and a better early outcome in comparison with Palmaz Schatz 34 .
Study limitations
Our experimental model, already refined in previous studies 12 , appears safe and reliable and could be proposed to assess the haemocompatibility of stents before their clinical utilisation.
However, since alterations of the thrombogenic pathways have been proven in atherosclerotic patients 35 , possibly influencing the outcome of stenting procedures, then the use of blood from healthy volunteers could have represented a limitation.
Moreover, the absence of an endothelial layer in the circulating system may have altered the likelihood of our experimental representation. In fact, through the release of cytokines and the expression of adhesion molecules, endothelium has a major role in mediating the interplay between the injured vessel wall and blood cells after coronary stenting 36 . Finally, the well-known in-vitro inefficacy of platelet ADP-receptor inhibitors 37 prevented to investigate the possible additional effects of a double antiplatelet regimen.
Conclusions
Immunofluorocytometry and scanning electron microscopy demonstrate that, compared to a traditional stainless-steel stent, MultiLink is a device with features of reduced thrombogenicity and improved haemocompatibility. This evidence supports the excellent immediate and long-term clinical results achieved with this stent.
Single antiplatelet treatment could be proposed as the treatment of choice to prevent platelet deposition when MultiLink stent is used.
